|
1) Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritopic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-92
|
|
|
|
2) Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 1989; 6: 193-210
|
|
|
|
|
|
3) Muggia FM. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res. 1999; 5: 7-8
|
|
|
|
|
|
4) Gabizon A, Chemla M, Tzemach D, et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumor and therapeutic efficacy of encapsulated anthracyclines. J Drug Targeting. 1996; 3: 391-8
|
|
|
|
|
|
5) Sakakibara T, Chen F-A, Kida H, et al. Doxorubicin encapsulated in sterically stabilized liposomes in superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res. 1996; 56: 3743-6
|
|
|
|
|
|
6) Unezaki S, Maruyama K, Hosoda J-I, et al. Direct measurement of the extravasation of poly-ehyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharmaceut. 1996; 144: 11-7
|
|
|
|
|
|
7) Lasic D. Doxorubicin in sterically stabilized liposomes. Nature. 1996; 380: 561-2
|
|
|
|
|
8) Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally adcanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001; 7: 243-54
|
|
|
|
|
|
9) Koukourakis MI, Koukouraki S, Giatramanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999; 17: 3512-21
|
|
|
|
|
|
10) Northfelt DW, Martin FJ, Working P. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics. Tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996; 36: 55-63
|
|
|
|
|
|
11) Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Annals Oncol. 2000; 11: 1029-33
|
|
|
|
|
|
12) Ryan C, Fleming G, Janisch L, et al. A phase I study of liposomal doxorubicin (DOXIL) with topotecan. Am J Clin Oncol. 2000; 23: 297-300
|
|
|
|
|
|
13) Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999; 10: 1113-6
|
|
|
|
|
|
14) Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-22
|
|
|
|
|
|
15) Nyman DW, Compbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005; 23: 7785-93
|
|
|
|
|
|
16) Sparreboom A, Baker SD, et al. Paclitaxel repackaged in an albumin-stabilized nano-particle: Handy or just a dandy？ J Clin Oncol. 2005; 23: 7765-7
|
|
|
|
|
|
17) Hamaguchi T, Kato K, Matsumura Y, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Brit J Cancer. 2007; 97: 170-6
|
|
|
|
|
|
18) Mizumura Y, Matsumura Y, Yokoyama M, et al. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity. Jpn J Cancer Res. 2002; 11: 1237-43
|
|
|
|
|
|
19) Uchino H, Matsumura Y, Negishi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Brit J Cancer. 2005; 93: 678-87
|
|
|
|
|
|
20) Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38-incorporated polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66: 10048-56
|
|
|
|
|